Personalized Medicine Has a Quantifiable ROI

OPEN MINDS Weekly News Wire Strategic Health Care News Personalized medicine for breast cancer treatment could produce a positive return on investment (ROI) according to a recent study. Consumers had a strong ROI from the onset or experienced a positive ROI only after 4.4 years. Payers had a positive ROI after 6.35 years or did not achieve a positive ROI in terms of their per-member per-month costs. Diagnostic test companies experienced constant positive ROI throughout, or had a slightly negative ROI with no demonstrated breakeven point. Biotech and pharmaceutical companies experienced a negative ROI in one . . .